Microengineered in vitro CAR T cell screens and assays

Area of Science:

• Biotechnology and Biomedical Engineering
• Immunotherapy
• Cellular Engineering

Background:

• Chimeric antigen receptor (CAR) T-cell therapy shows promise but requires rigorous product evaluation.
• Existing methods for assessing CAR T-cell products have limitations in scope and throughput.
• Microengineered in vitro systems offer novel solutions for comprehensive CAR T-cell analysis.

Purpose of the Study:

• To describe microengineered in vitro systems for evaluating CAR T-cell products.
• To demonstrate how these systems optimize CAR T-cell products through cell selection and avidity tailoring.
• To explore future directions in CAR T-cell therapy development and manufacturing.

Main Methods:

• Utilizing microengineered systems for high-throughput screening of CAR T-cell functionality.
• Implementing strategies for selecting viable and eliminating off-target cells.
• Tailoring CAR T-cell avidity to achieve a balance between therapeutic efficacy and patient safety.

Main Results:

• Demonstrated ability to assess CAR T-cell product purity, avidity, and functionality.
• Successfully optimized CAR T-cell products by enhancing cell viability and reducing off-target effects.
• Established a framework for a cyclical development and manufacturing process for CAR T-cell therapies.

Conclusions:

• Microengineered in vitro systems are critical tools for advancing CAR T-cell therapy.
• These systems facilitate the optimization of CAR T-cell products for enhanced safety and efficacy.
• The integration of high-throughput and patient-centered techniques will shape the future of CAR T-cell manufacturing.